Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059643 | 0.83 | KCNA5 (0.49) | SMN1; SMN2KCNA5KCNH2SLC22A12GABRA1 | |
| SCHEMBL3064355 | 0.82 | KCNA5 (0.39) | SMN1; SMN2MGLLKCNA5KCNH2CYP19A1 | |
| SCHEMBL4380408 | 0.81 | CYP19A1 (0.42) | SMN1; SMN2KCNA5CYP19A1VNN1GRM4 | |
| SCHEMBL1507787 | 0.81 | TSHR (0.48) | SMN1; SMN2MGLLGRM4S1PR3 | |
| SCHEMBL30961611 | 0.81 | TSHR (0.48) | SMN1; SMN2MGLLGRM4S1PR3 | |
| SCHEMBL3074853 | 0.81 | VNN1 (0.38) | MGLLKCNA5KCNH2CYP19A1SLC22A12 | |
| SCHEMBL3068022 | 0.79 | VNN1 (0.48) | SMN1; SMN2VNN1S1PR3 | |
| SCHEMBL9197340 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2MGLLKCNA5KCNH2CYP19A1 | |
| SCHEMBL13138815 | 0.76 | SMN1; SMN2 (0.43) | SMN1; SMN2KCNA5KCNH2GAA | |
| SCHEMBL3064453 | 0.74 | KCNA5 (0.53) | KCNA5KCNH2SLC22A12GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101128431-B | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA NV | 2011-05-25 | — | — | CN | disclosed |
| US-7790895-B2 | Quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7790895-B2 | Quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7671065-B2 | Pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-02 | — | — | US | disclosed |
| US-7671065-B2 | Pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-02 | — | — | US | disclosed |
| CN-101128431-A | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-20 | — | — | CN | disclosed |
| CN-101128428-A | Pyridine derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-20 | — | — | CN | disclosed |
| EP-1858853-A2 | NOVEL PYRIDINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-28 | — | — | EP | disclosed |
| EP-1853564-A1 | NOVEL QUINOLINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | Janssen Pharmaceutica N.V. (BE) | 2007-11-14 | — | — | EP | disclosed |
| US-20070054936-A1 | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-20070054936-A1 | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-20070054935-A1 | Novel pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-20070054935-A1 | Novel pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| WO-2006091769-A1 | NOVEL QUINOLINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006091800-A2 | NOVEL PYRIDINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054936-A1 | Novel quinoline derivatives as potassium ion channel openers | KCNQ1, KCNQ2, KCNJ2 | SMN1; SMN2 1987/4885MGLL 3584/4885KCNA5 25/4885 |
| US-20070054935-A1 | Novel pyridine derivatives as potassium ion channel openers | KCNJ2, KCNQ2, KCNQ1 | SMN1; SMN2 963/4885MGLL 3855/4885KCNA5 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.